4.5 Article

National survey of malignant mesothelioma and asbestos exposure in Japan

Journal

CANCER SCIENCE
Volume 103, Issue 3, Pages 483-490

Publisher

WILEY
DOI: 10.1111/j.1349-7006.2011.02165.x

Keywords

-

Categories

Funding

  1. research foundation of the Ministry of Health, Labour and Welfare of Japan [200500129A, 200635021A, 200733015A, 200733015B, 200836010A, 200938007A, 201032004B]

Ask authors/readers for more resources

In the present study, malignant mesothelioma (MM) cases in Japan were investigated retrospectively. We extracted records for 6030 cases of death due to MM between 2003 and 2008 to clarify the clinical features of MM, including its association with asbestos exposure (AE). Of all these cases, a clinical diagnosis of MM was confirmed for 929. The origin of MM included the pleura in 794 cases (85.5%), the peritoneum in 123 cases (13.2%), the pericardium in seven cases (0.8%), and the testicular tunica vaginalis in five cases (0.5%). The histological subtypes of MM included 396 epithelioid (55.9%), 154 sarcomatoid (21.7%), 126 biphasic (17.8%), and 33 cases (4.7%) classified as other types. Of all the MM cases, AE was indicated in 76.8% and pleural plaques were detected in 34.2%. The number of asbestos particles was determined in 103 cases of MM. More than 1000 asbestos particles per gram dried lung tissue were detected in 74.8% of cases and more than 5000 particles were detected in 43.7% of cases. We compared patient characteristics and the diagnostic procedures for MM before and after the Kubota shock. Compared with the early phase of this study (20032005), the median age at diagnosis of MM was higher, the number of cases without definite diagnosis of MM was lower, the proportion of cases diagnosed by thoracoscopy was higher, and the percentage of cases in which the occupational history was described in the medical records was significantly higher in the later phase (20062008). Our study confirmed that more than 70% of MM cases in Japan are associated with AE. The Kubota shock may affect some features pertaining to MM. (Cancer Sci 2012; 103: 483490)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

Katsuyuki Hotta, Nobukazu Fujimoto

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jeronimo Rodriguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gerard Zalcman

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

Article Oncology

Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol

Kazuya Nishii, Masaaki Inoue, Hideto Obata, Yutaka Ueda, Toshiyuki Kozuki, Masahiro Yamasaki, Tomonori Moritaka, Yoshikazu Awaya, Keisuke Sugimoto, Kenichi Gemba, Shoichi Kuyama, Hirohisa Ichikawa, Takuo Shibayama, Tetsuya Kubota, Masahiro Kodani, Daizo Kishino, Nobukazu Fujimoto, Nobuhisa Ishikawa, Yukari Tsubata, Tomoya Ishii, Kazunori Fujitaka, Katsuyuki Hotta, Katsuyuki Kiura

Summary: The umbrella-type CS-Lung-003 registry integrates multiple linked studies to address various clinical questions on daily practice patterns of lung cancer treatment. This collaborative approach enables researchers to generate results across multiple domains of study and provide answers to questions raised by other researchers. Through analysis of each linked study, the registry aims to comprehensively elucidate actual daily practice patterns in lung cancer treatment.

THORACIC CANCER (2021)

Article Oncology

The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment

Naoko Sueoka-Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda, Sunao Ushijima, Hitomi Umeguchi, Daijiro Harada, Kosuke Kashiwabara, Takayuki Suetsugu, Nobukazu Fujimoto, Fumihiro Tanaka, Hidetaka Uramoto, Chiharu Yoshii, Katsumi Nakatomi, Genju Koh, Nobuhiko Seki, Keisuke Aoe, Kaname Nosaki, Koji Inoue, Ayako Takamori, Atsushi Kawaguchi

Summary: This study investigated the predictive value of comprehensive NGS analysis of ctDNA in NSCLC patients treated with osimertinib after progressing on EGFR-TKI treatment. The study found that T790 M allele fraction in ctDNA and total number of alterations detected by NGS may be associated with treatment response and early resistance, respectively. Additionally, loss of T790 M was observed in 32% of patients after acquiring resistance to osimertinib.

CANCER MEDICINE (2021)

Article Critical Care Medicine

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

Timothy A. Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, Kozo Kuribayashi, Tormod Kyrre Guren, Luana Calabro, Ronnie Shapira-Frommer, Bo Gao, Steven Kao, Ignacio Matos, David Planchard, Arkendu Chatterjee, Fan Jin, Kevin Norwood, Hedy L. Kindler

Summary: Pembrolizumab demonstrated durable antitumor activity and manageable toxicity in patients with advanced MPM, regardless of PD-L1 status. Our data support the programmed death 1 (PD-1) and PD-L1 pathway as a potential therapeutic target in some patients with previously treated mesothelioma but biomarkers that can effectively identify such patients are yet to be elucidated.

LANCET RESPIRATORY MEDICINE (2021)

Article Multidisciplinary Sciences

Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion

Takumi Kishimoto, Yoko Kojima, Nobukazu Fujimoto

Summary: SLPI levels in pleural effusion can help distinguish between benign asbestos pleural effusion (BAPE) and early-stage malignant pleural mesothelioma (MPM). The combination of SLPI and CYFRA21-1 biomarkers can improve the differentiation between BAPE and MPM.

SCIENTIFIC REPORTS (2021)

Article Oncology

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

S. Peters, A. Scherpereel, R. Cornelissen, Y. Oulkhouir, L. Greillier, M. A. Kaplan, T. Talbot, I Monnet, S. Hiret, P. Baas, A. K. Nowak, N. Fujimoto, A. S. Tsao, A. S. Mansfield, S. Popat, X. Zhang, N. Hu, D. Balli, T. Spires, G. Zalcman

Summary: In patients with unresectable malignant pleural mesothelioma, first-line nivolumab plus ipilimumab showed continued long-term survival benefit over chemotherapy with a manageable safety profile, based on 3 years of follow-up data.

ANNALS OF ONCOLOGY (2022)

Article Oncology

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto

Summary: The JME-001 trial aimed to evaluate the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma. Preliminary results showed a high objective response rate and disease control rate in the majority of patients, but also a significant rate of adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Kenichiro Kudo, Kazuya Nishii, Go Makimoto, Nobuhisa Ishikawa, Yukari Tsubata, Masahiro Kodani, Nobukazu Fujimoto, Masahiro Yamasaki, Tetsuya Kubota, Nagio Takigawa, Kazunori Fujitaka, Nobuhiro Kanaji, Takuo Shibayama, Junko Itano, Chihiro Ando, Katsuyuki Hotta, Katsuyuki Kiura

Summary: Repeat rebiopsy may increase the ability to detect T790M mutation positivity rate in patients with T790M-negative non-small-cell lung cancer (NSCLC) detected by the first rebiopsy.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Article Oncology

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, Francesco Grossi, Dariusz Kowalski, Gerard Zalcman, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Xiaowu Sun, Rachael Lawrance, Xiaoqing Zhang, Melinda J. Daumont, Bryan Bennett, Mike McKenna, Paul Baas

Summary: Nivolumab + ipilimumab significantly prolonged overall survival and improved disease-related symptoms and health-related quality of life in patients with unresectable malignant pleural mesothelioma. Compared to chemotherapy, Nivolumab + ipilimumab reduced the risk of symptom and quality of life deterioration and delayed disease progression.

LUNG CANCER (2022)

Article Medicine, General & Internal

Severe cardiotoxicity induced by osimertinib in a patient with EGFR-mutated adenocarcinoma of the lung

Takaaki Tanaka, Soma Nii, Hidenaru Yamaoka, Nobukazu Fujimoto

Summary: A man in his 70s was diagnosed with adenocarcinoma of the lung and received carboplatin, paclitaxel, and thoracic radiotherapy. After recurrence, he was treated with osimertinib, which eventually led to cardiac failure. Discontinuation of osimertinib resulted in gradual improvement in cardiac function. Osimertinib-related cardiotoxicity should be taken into consideration.

BMJ CASE REPORTS (2023)

Article Oncology

Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan

Seiki Hasegawa, Yasushi Shintani, Teruhisa Takuwa, Keisuke Aoe, Katsuya Kato, Nobukazu Fujimoto, Yasuhiro Hida, Masahiro Morise, Yasumitsu Moriya, Takao Morohoshi, Hidemi Suzuki, Masayuki Chida, Shunsuke Endo, Mitsutaka Kadokura, Meinoshin Okumura, Satoshi Hattori, Hiroshi Date, Ichiro Yoshino

Summary: A nationwide prospective registry for newly diagnosed and untreated pleural mesothelioma in Japan was conducted, and data on patients' survival were collected. The study found that surgery significantly prolonged overall survival, and tumor shape and thickness were important prognostic factors.

CANCER SCIENCE (2023)

Article Oncology

Survival of chemo-naive patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404

Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, Daijiro Harada, Toshio Kubo, Kadoaki Ohashi, Eiki Ichihara, Shoichi Kuyama, Kenichiro Kudo, Akihiro Bessho, Makoto Sakugawa, Nobukazu Fujimoto, Keisuke Aoe, Daisuke Minami, Keisuke Sugimoto, Nobuaki Ochi, Nagio Takigawa, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

Summary: This study demonstrated that combination therapy with afatinib and bevacizumab may improve survival outcomes in patients with EGFR-mutant advanced non-small-cell lung cancer, showing promise for future treatment options.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Medicine, General & Internal

Catamenial pneumothorax due to heterotopic endometriosis in the pericardium

Yuki Takigawa, Daisuke Mizuno, Norichika Iga, Nobukazu Fujimoto

Summary: This report describes a case of a 46-year-old woman who presented with pneumothorax during menstruation and underwent multiple surgeries. The blueberry spot in the pericardium was identified as the source of bleeding during reoperation, confirming the diagnosis of heterotopic endometriosis.

BMJ CASE REPORTS (2021)

Article Oncology

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)

Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Hisashi Tanaka, Megumi Inaba, Terunobu Haruyama, Junya Nakamura, Takayuki Kishikawa, Masanao Nakashima, Keiichi Iwasa, Keiichi Fujiwara, Tadashi Kohyama, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Hiroo Ishida, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Toshihide Yokoyama, Kenichi Gemba, Takeshi Tsuda, Hideyuki Nakagawa, Hirotaka Ono, Tetsuo Shimizu, Morio Nakamura, Sojiro Kusumoto, Ryuji Hayashi, Hiroki Shirasaki, Nobuaki Ochi, Keisuke Aoe, Nobuhiro Kanaji, Kosuke Kashiwabara, Hiroshi Inoue, Nobuhiko Seki

Summary: This study aims to evaluate the efficacy and safety of consolidation therapy with durvalumab following the SP regimen in Japanese patients with LA-NSCLC, with a focus on PFS and OS. The SP regimen is expected to have lower incidences of adverse effects and higher success rates in transitioning to durvalumab after chemoradiotherapy, potentially leading to improved outcomes.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

No Data Available